2016 American Transplant Congress

Monday, June 13, 2016

6:00pm-7:00pm

Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.

C. Burton, Y. Tong, J. Preiksaitis.

Poster Session C: Viruses and SOT  •  Halls C&D

6:00pm-7:00pm

Intra-Operative Hepatic Arterial Flow Predicts Hepatic Artery Complications After Deceased Donor Liver Transplantation.

H. Fernandez, G. Testa, G. Klintmalm, P. Kim.

Poster Session C: Liver Transplantation Complications and Other Considerations  •  Halls C&D

6:00pm-7:00pm

Is Early Endoscopic Retrograde Cholangiopancreatography (ERCP) Safe Post Liver Transplant?

B. Wolk,¹ A. Shiani,² S. Lipka,² A. Kumar,² N. Kemmer,¹ H. Pinkas,² A. Alsina,¹ P. Brady,² A. Turner.¹

Poster Session C: Liver Transplantation Complications and Other Considerations  •  Halls C&D

6:00pm-7:00pm

Is It Worth Risking Lives of Multiple Procurement Surgeons to Save One Life in Extreme Weather Conditions?

H. Sharma, I. Al-Hasan, M. Richard, O. Ali, A. Sener, D. Quan, V. Macillister.

Poster Session C: Economics, Public Policy, Allocation, Ethics  •  Halls C&D

6:00pm-7:00pm

IVIG and High Dose Steroid Treatment of Transplant Glomerulopathy Effectively Slows Progression of Loss of Renal Allograft Function.

K. Sablik,¹ C. Looman,² M. Clahsen-van Groningen,³ J. Damman,³ D. Roelen,⁴ M. van Agteren,¹ M. Betjes.¹

Poster Session C: Antibody Mediated Rejection: Session #1  •  Halls C&D

6:00pm-7:00pm

Japanese Multicenter Study of Hepatopulmonary Syndrome in Living Donor Liver Transplantation.

H. Egawa, S. Ogata.

Poster Session C: Liver Transplantation Complications and Other Considerations  •  Halls C&D

6:00pm-7:00pm

KDPI Outcomes and Discard Rates – The Contradiction of the U.S. and European Approach.

L. Lehner, A. Kleinsteuber, F. Halleck, D. Khadzhynov, M. Duerr, K. Budde, O. Staeck.

Poster Session C: Economics, Public Policy, Allocation, Ethics  •  Halls C&D

6:00pm-7:00pm

Kidney Graft Homing of De Novo Donor Specific HLA Antibodies Is an Early Step within the Antibody-Mediated Graft Damage Process.

A. Nocera,¹ M. Cioni,² A. Tagliamacco,¹ A. Innocente,³ I. Fontana,⁴ A. Magnasco,² A. Nocco,³ A. Sementa,² G. Garibotto,¹ G. Ghiggeri,² M. Cardillo,³ P. Comoli,⁵ F. Ginevri.²

Poster Session C: Antibody Mediated Rejection: Session #1  •  Halls C&D

6:00pm-7:00pm

Kidney Transplant Induction Therapies: Risks of Death, Allograft Failure, Sepsis, and Cancer.

N. Koyawala,¹ J. Silber,² P. Rosenbaum,¹ R. Bloom,¹ W. Wang,² A. Hill,² S. Nazarian,¹ D. Sawinski,¹ J. Trofe,¹ M. Lim,¹ J. Schold,³ P. Reese.¹

Poster Session C: Clinical Science - Kidney Immunosuppression: Induction Therapy  •  Halls C&D

6:00pm-7:00pm

Kidney Transplant Outcomes in Patients with CPRA Values >98% After Implementation of the New OPTN/UNOS Kidney Allocation System (KAS): A Single Center Study Update.

N. Kaur,¹ S. Goral,¹ J. Kearns,² P. Abt,³ A. Naji,³ P. Porrett,³ M. Levine,³ M. Kamoun.²

Poster Session C: Kidney Transplantation: AKI/Preservation/DCD  •  Halls C&D